Glucagon-like peptide-1 receptor agonists (GLP1-RAs), used for type 2 diabetes (T2D) and obesity, modulated dopamine reward signaling and decreased drug rewards, including heroin in rodents.3 Anecdotal reports of reduced drug craving in individuals using semaglutide, a new generation GLP-1RA, along with empirical studies showed its therapeutic benefits in alcohol and nicotine use disorders.4,5 This led us to investigate whether semaglutide could protect against overdoses in patients with OUD. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.